Recombinant TFPI (Concizumab Biosimilar) anticorps
Aperçu rapide pour Recombinant TFPI (Concizumab Biosimilar) anticorps (ABIN7675920)
Antigène
Type d'anticorp
Reactivité
Hôte
Clonalité
Conjugué
Application
-
-
Expression System
- CHO Cells
-
Fonction
- Anti-TFPI Reference Antibody (concizumab)
-
Séquence
- EVQLVESGGG LVKPGGSLRL SCAASGFTFS NYAMSWVRQT PEKRLEWVAT ISRSGSYSYF PDSVQGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARLG GYDEGDAMDS WGQGTTVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK,DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL ESDGKTYLNW YLQKPGQSPQ LLIYLVSILD SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQATHFP QTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
Attributs du produit
- Anti-TFPI Reference Antibody (concizumab) is expressed from CHO. The heavy chain type is huIgG4SP, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Pureté
- >95 %
-
Isotype
- IgG4 S228P
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Commentaires
-
Therapeutic Agents by Target and Mechanism: TFPI inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Stock
- 4 °C,-80 °C
-
Stockage commentaire
- +4°C,-80°C
-
-
- TFPI (Concizumab Biosimilar)
-
Classe de substances
- Biosimilar
-
Poids moléculaire
- 145.5 kDa
-
UniProt
- P10646
Antigène
-